YM BIOSCIENCES INC. - FDA clearance for new trial.

PR Newswire UK Disclose, June, 2007

 
YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain 
Product AeroLEF(TM) 
 
    - YM to initiate trial in the U.S. and plans End of Phase II meeting with 
    FDA - 
 
    MISSISSAUGA, ON, June 27 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, 
AIM: YMBA), an oncology company that identifies, develops and commercializes 
differentiated products for patients worldwide, today announced that the U.S. 
Food and Drug Administration (FDA) has cleared its Investigational New Drug 
(IND) application for AeroLEF(TM). 
    AeroLEF(TM) is a unique, inhaled-delivery composition of free and 
liposome-encapsulated fentanyl in development for the treatment of moderate to 
severe pain, including cancer pain. In contrast to fixed-dose approaches to 
opioid delivery,...

            
        
    
    	    
                
                
	

		

					 
            Read the rest of this article with a Free Trial at HighBeam Research.
        				
 

    		            
	
                Premium Content Partnership | 
                	HighBeam Research provides an in-depth online archive library of reference works.